Karyopharm to Participate at the Jefferies Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 a.m. ET, in New York, NY. The event will feature the senior management team and will be accessible via live webcast on the company's Investor website, with replays available for 90 days after the conference. Karyopharm specializes in innovative cancer therapies, including its XPOVIO® (selinexor), which targets various high unmet cancer needs.
- None.
- None.
NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m. ET in New York, NY.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®), China and Singapore. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-healthcare-conference-301558331.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm participate in the Jefferies Healthcare Conference?
What time is Karyopharm's fireside chat at the Jefferies Healthcare Conference?
Where can I watch the Karyopharm fireside chat?
What is the main focus of Karyopharm Therapeutics?
What is XPOVIO® and what indications does it target?
